Immunohistochemical profiling based on Bcl‐2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is poorly predictable. Expression of proteins related to germinal centre B (GCB) cell or activated B cells (ABC) and expression of apoptosis‐regulating proteins Bcl‐2 and XIAP have been found previously to be strongly associated with clinical outcome. In this study we aimed to develop an algorithm based on expression of GCB/ABC‐related proteins CD10, Bcl‐6 and MUM1 and apoptosis‐inhibiting proteins Bcl‐2, XIAP and cFLIP for optimal stratification of DLBCL patients into prognostically favourable and unfavourable groups. Expression of CD10 and cFLIP was associated with better overall survival (both p = 0.03), whereas expression of MUM1, Bcl‐2 and XIAP was associated with poor clinical outcome (p = 0.01, p = 0.0007 and p = 0.03, respectively). Multivariate analysis revealed that Bcl‐2 was the strongest prognostic marker followed by CD10 and MUM1. Stratification of patients according to a new algorithm based on expression of these three markers improved patient risk stratification into low and particularly high clinical risk groups (p = 0.04 and p < 0.0001, respectively). We conclude that, in our group of primary nodal DLBCLs, a new algorithm, based on expression of the apoptosis‐inhibiting protein Bcl‐2 and the GCB/ABC‐related proteins CD10 and MUM1, strongly predicts outcome in International Prognostic Index (IPI)‐low and ‐high patients. Its predictive power is stronger than previously published algorithms based on only GCB/ABC‐ or apoptosis‐regulating proteins. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  R. Rosenquist,et al.  Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis , 2005, Modern Pathology.

[2]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Schmitz,et al.  The best treatment for diffuse large B-cell lymphoma: a German perspective. , 2005, Oncology.

[4]  S. Horvath,et al.  Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases , 2005, Clinical Cancer Research.

[5]  C. Gundy,et al.  Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. , 2005, Blood.

[6]  R. Taulli,et al.  15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. , 2005, Blood.

[7]  Yasodha Natkunam,et al.  Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.

[8]  L. Staudt,et al.  Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .

[9]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[10]  Chung-Che Chang,et al.  Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma , 2004, The American journal of surgical pathology.

[11]  C. Meijer,et al.  Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas , 2004, Leukemia.

[12]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[13]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Gaulard,et al.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.

[15]  S. Kvaløy,et al.  Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  V. Callea,et al.  Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro. , 2003, Haematologica.

[17]  Emili Montserrat,et al.  Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. , 2003, Blood.

[18]  M. Teitell,et al.  PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling , 2002, Nature Immunology.

[19]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[20]  M. Dono,et al.  CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL , 2002, British Journal of Cancer.

[21]  S. Barrans,et al.  Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. , 2002, Blood.

[22]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[23]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[24]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[25]  J. Medema,et al.  Cutting Edge: Cellular Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Inhibitory Protein Protects Germinal Center B Cells from Apoptosis During Germinal Center Reactions , 2001, The Journal of Immunology.

[26]  P. Krammer,et al.  Flice-Inhibitory Protein Is a Key Regulator of Germinal Center B Cell Apoptosis , 2001, The Journal of experimental medicine.

[27]  K. Franssila,et al.  Causes and Consequences of BCL2 Overexpression in Diffuse Large B-Cell Lymphoma , 2001, Leukemia & lymphoma.

[28]  M. Ferrarini,et al.  Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. , 1999, Blood.

[29]  S. Lowe,et al.  Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. , 2001, Blood cells, molecules & diseases.

[30]  P. Krammer,et al.  Regulation of the Fas Death Pathway by FLICE-Inhibitory Protein in Primary Human B Cells1 , 2000, The Journal of Immunology.

[31]  Guido Kroemer,et al.  Mitochondrial control of cell death , 2000, Nature Medicine.

[32]  C. Gélinas,et al.  The Rel/NF-κB Family Directly Activates Expression of the Apoptosis Inhibitor Bcl-xL , 2000, Molecular and Cellular Biology.

[33]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[34]  A. Lobito,et al.  Inhibition of Fas‐mediated apoptosis by the B cell antigen receptor through c‐FLIP , 2000, European journal of immunology.

[35]  F. Cavalli,et al.  Extranodal lymphomas. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  O. Bairey,et al.  Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  S. Korsmeyer.  BCL-2 gene family and the regulation of programmed cell death. , 1995, Cancer research.

[38]  C. Thompson,et al.  The central effectors of cell death in the immune system. , 1999, Annual review of immunology.

[39]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[40]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[42]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.

[43]  J Hermans,et al.  Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Gaulard,et al.  Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma , 1996 .

[45]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[46]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[47]  D.,et al.  Regression Models and Life-Tables , 2022 .